SCTX · NASDAQ
Scribe Therapeutics (SCTX) Stock Price & Fundamentals
Scribe Therapeutics (SCTX) closed at $875.15 on Oct 9, 2026, up less than 0.01% from the previous close of $875.12.
Share price, past year
1Y +17.59%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $875.15 |
| Sep 30, 2026 | $861.84 |
| Aug 31, 2026 | $864.29 |
| Jul 31, 2026 | $841.31 |
| Jun 30, 2026 | $820.60 |
| May 29, 2026 | $764.87 |
| Apr 30, 2026 | $787.00 |
| Mar 31, 2026 | $755.78 |
| Feb 27, 2026 | $700.72 |
| Jan 30, 2026 | $717.70 |
| Dec 31, 2025 | $697.42 |
| Nov 28, 2025 | $707.61 |
| Oct 31, 2025 | $777.13 |
Key statistics
- Market cap
- $16.57B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 18.9M
- Dividend yield
- —
- 52-week range
- $677.30 – $875.45
Scribe Therapeutics's market cap is $16.57B, based on a share price of $875.15 and 18.9M shares outstanding as of Aug 31, 2026.
Financials
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.92M | −$6.48M | −$2.62 |
| Q1 FY2026ended Mar 31, 2026 | $2.23M | −$17.35M | −$7.03 |
| Q2 FY2025ended Jun 30, 2025 | $4.90M | −$9.90M | −$4.08 |
| Q1 FY2025ended Mar 31, 2025 | $17.13M | −$3.43M | −$1.42 |
Earnings
Scribe Therapeutics lost $2.62 per share in fiscal Q2 2026, reported Sep 2, 2026, compared with a loss of $4.08 a year earlier.
Diluted earnings per share by quarter
| Quarter | Reported | EPS (diluted) | A year earlier | Change |
|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Sep 2, 2026Earnings release | −$2.62 | −$4.08 | — |
| Q1 FY2026ended Mar 31, 20266 months minus last 3 months | — | −$7.03 | −$1.42 | — |
| Q2 FY2025ended Jun 30, 2025 | — | −$4.08 | — | — |
| Q1 FY2025ended Mar 31, 20256 months minus last 3 months | — | −$1.42 | — | — |
About Scribe Therapeutics
- Name
- Scribe Therapeutics, Inc.
- Ticker
- SCTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 1150 Marina Village Pkwy, Alameda, CA 94501
- Incorporated in
- Delaware
- Fiscal year ends
- December
- SEC CIK
- 0001853921
Recent SEC filings
- Sep 2, 2026
- Sep 2, 2026
- Jul 27, 2026
ETFs that hold Scribe Therapeutics
Of the ETFs and funds on Laurel, ARK Genomic Revolution ETF (ARKG) holds the most Scribe Therapeutics shares by value: 0.44% of the fund, as of its latest report to the SEC.
Frequently asked questions
What is Scribe Therapeutics's stock price?
Scribe Therapeutics (SCTX) closed at $875.15 on Oct 9, 2026, up less than 0.01% from the previous close of $875.12.
What is Scribe Therapeutics's market cap?
Scribe Therapeutics's market cap is $16.57B, based on a share price of $875.15 and 18.9M shares outstanding as of Aug 31, 2026.
Sources and methodology
Fundamentals come from Scribe Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 10, 2026. Data sources and disclosures